Tag Archives: National Institutes of Health

Adhere to the PKU Diet by Adhering to Each Other

Whether you call it compliance, adherence or some other politically correct term, maintaining a well-controlled PKU diet can be just plain hard! Some might think that as you get older and the longer you’ve been living with PKU, then the easier it gets to stick with it. It’s quite the contrary though. Instead, there are challenges at every stage of a PKU patient’s life…everything from infancy and adolescence, to adulthood and maternal PKU.

Five Dimensions of Medical Adherence, PKU, Low-Protein Diet, Phenylketonuria

Source: World Health Organization, 2003

Much research has been conducted to examine some of the factors that impact a person’s adherence to the PKU diet. In fact, the World Health Organization recognizes five dimensions to medical adherence: social/economic factors, provider-patient/health care system factors, condition-related factors, therapy-related factors, and patient-related factors. Another health organization, the National Institutes of Health, took a closer look at how some of these dimensions applied to the treatment of PKU:

  • Complexity of the treatment – requiring regular blood samples; daily diet records; maintenance of a highly restrictive diet consisting of a medical food, special low protein foods, and a strict vegetarian diet; and visiting a PKU clinic several times a year.
  • Palatability – having to do with whether the medical food tastes good, has an appealing texture, and smells appetizing.
  • Accessibility – specifically, barriers to insurance coverage and inability to cover medical costs.
  • Portability – dealing with the challenges in eating low-protein when at school or work, when traveling on vacation, or any other time you find yourself away from home.
  • Peer pressure – mainly dealing with adolescent patients who are seeking more independence from their parents and looking for acceptance among their peers.
  • Family factors – related to the education level of the PKU patient’s parents and the willingness of extended family to support the PKU diet.

Honestly, entire blog posts could be devoted to each of these, but there’s something to be said for looking at these barriers as a whole. The reality of living with PKU is that patients must live with the combined burden of each of these factors – not to mention the chronic, no-cure status of the genetic disorder – all of which can just wear you out!

There is some good news though. We’ve all experienced our own trials and tribulations, but more than likely, we’ve also had our happy endings. The PKU community consists of a strong network of individuals who have adapted when necessary, learned to innovate when the situation demanded it, and most importantly, shared their experiences with others who might also benefit from their lessons learned.

For example, here are just a few tips for adhering to the PKU diet, all of which were shared among attendees at a recent PKU cooking workshop in Chattanooga, TN:

  • Parents should acknowledge any frustration their PKU child might express about being on diet, but they should also realize that “it is what it is.” Parents who say they feel bad or guilty that their child has diet restrictions will only enable adherence issues.
  • Recognize that we shouldn’t just treat the diet, but we should also address the emotional side that comes with PKU.
  • For fitting in at school, parents can arrange introductory PKU meetings with their child’s teachers or cafeteria workers; send Rubbermaid tubs with PKU friendly snacks for when other students bring in high-protein birthday treats to share with the class; and role play with your child so he/she becomes comfortable with answering questions about PKU.
  • For fitting in at work, pack your lunch and several low-protein snacks. If a group goes out for lunch, consider eating before they go or take your lunch with you to the restaurant. Many restaurants have low-protein items you can order from the menu. Be sure to surround yourself with friends who know about PKU – you might be surprised to see them start explaining PKU for you when others ask. And believe it or not, role playing can also work with adult PKU patients.

Certainly, these are all great suggestions, but I’m willing to bet you also have a tip or piece of advice worth sharing. If so, please tell me about it in the comments field below!

–NM

8 Comments

Filed under Research, Lo-pro Diet Management

Maternal PKU and Sapropterin

This past February, the National Institutes of Health (NIH) hosted a scientific review conference on Phenylketonuria to discuss the “state of the science and future research needs.” The event was free and open to the public, but even if you could not cover the cost of travel and accommodations, the two-day event was also broadcasted live via webcast. I managed to log-on during my lunch break and listened intently to a session on PKU and Pregnancy. To my surprise, much of the PKU and Pregnancy presentation focused on Sapropterin and its use during maternal PKU (Sapropterin is the generic name for Kuvan, the first prescription drug approved by the U.S. Food and Drug Administration to lower blood phe levels in PKU patients).

To be clear, Kuvan is not recommended for maternal PKU unless the benefits outweigh the risks. That is because when ranked on the FDA’s pregnancy classification of drugs, Sapropterin is considered a category C drug since it is still unclear whether Sapropterin crosses the human placenta.

Research presented at the NIH conference confirmed that in some rare instances, Sapropterin had been prescribed to pregnant PKU patients, but only when the woman could not achieve dietary control at the start of her pregnancy. As early as 2005, Sapropterin was the focus of a study led by medical pioneer and PKU advocate Dr. Richard Koch. The patient was responsive to Sapropterin and during her pregnancy, she continued the medication at 40, 60, and 100 mg per day in the first, second, and third trimesters. Used in combination with low-protein food, optimal phe levels were achieved without any nausea and vomiting. More importantly, the woman’s child was born normal. Four years later, another study conducted by one of the presenters, Dr. Gabriella Pridjian from Tulane Hayward Genetics Center, reported on another pregnant PKU patient who had difficulty tolerating low-phe protein supplements. She was instructed to divide the Sapropterin up twice daily and ultimately had a healthy baby delivered through c-section. Pridjian noted that there were plans to eventually formally test the baby (who was now three years old) for any intellectual or developmental issues.

In addition to these two case studies, the NIH panel reported that other pregnancies involving the use of Sapropterin were currently underway. In addition to concerns about whether Sapropterin harms a developing fetus, doctors admitted it was hard to determine if symptoms such as headache, rhinorrhea, vomiting, fever, abdominal pain, rashes or nasal congestion were a result of the prescription drug or simply associated with the pregnancy.

Even though the maker of Kuvan, BioMarin, does in fact encourage pregnant women who were exposed to Kuvan during their pregnancy to participate in ongoing studies about the drug’s effect, there are no plans for future controlled studies. Based on what little has been conducted, including the two case studies I’ve mentioned here, initial reports of using Sapropterin during pregnancy are encouraging. However, continued research on this matter is definitely a must, especially with concern to the long-term implications the drug might have on a PKU woman’s child.

–NM

3 Comments

Filed under Conferences & Events, Kuvan, Maternal PKU, Research